Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$485.99 USD
+4.10 (0.85%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $486.28 +0.29 (0.06%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum D VGM
Brokerage Reports
Vertex Pharmaceuticals Incorporated [VRTX]
Reports for Purchase
Showing records 321 - 329 ( 329 total )
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Bulls and Bears Balancing Out at EASL - What to Expect Next?
Provider: WEDBUSH SECURITIES INC.
Analyst: XU K
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Q1:10 Earnings Non-Event; Phase III Data Next
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
EASL 2010 Preview Part I.Summary of Oral Presentations.
Provider: WEDBUSH SECURITIES INC.
Analyst: XU K
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: MERRIMAN CURHAN FORD & CO.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Uneventful Q4:09 Financials; Telaprevir-Boceprevir Phase III Data Showdown Next
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet.
Provider: MERRIMAN CURHAN FORD & CO.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Downgrading to Relative UNDERPERFORM on Valuation; Maintaining $45 PT.
Provider: WEDBUSH SECURITIES INC.